Clinical trials
NASH clinical trials
Below are recruiting nash clinical trials, each written for real people, not researchers. We’re tracking 37 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06215716RecruitingPhase 3
Efruxifermin for NASH/MASH with liver scarring
This study tests a new medicine, efruxifermin, for people with NASH/MASH (fatty liver disease) and moderate liver scarring. It aims to see if the drug can help improve the liver's condition.
Birmingham, AlabamaAges 18–80 - NCT04442334Recruiting
European registry for people with fatty liver
This registry collects health and lifestyle information from adults with suspected or confirmed fatty liver (NAFLD) to help researchers better understand the condition. You may be asked about diet, exercise, alcohol intake, and some liver-related tests.
AntwerpAges 18–100 - NCT06308757Recruiting
Studying a very low calorie keto diet for fatty liver disease with scarring
This trial tests whether a very low calorie ketogenic diet (a strict low-carb, high-fat diet) can help people with non-alcoholic steatohepatitis (NASH) who have liver scarring. Participants will follow this diet for a year and have two liver biopsies to see if their liver health improves.
BolognaAges 18 years+ - NCT07553663RecruitingPhase 1
Testing a new liver disease treatment for fatty liver
This study tests how your body processes a new medication called miricorilant, designed to help people with fatty liver disease (MASH). You'll have liver scans or recent biopsy results and metabolic conditions like diabetes or high blood pressure.
San Antonio, TexasAges 18–75 - NCT07198386RecruitingPhase 2
Study of CS060380 tablets for NASH (fatty liver disease)
This trial tests an experimental pill called CS060380 for people with NASH (a type of fatty liver disease that can cause liver damage). You may qualify if you have a liver biopsy showing NASH with early-to-moderate scarring, or an MRI showing at least 10% liver fat, and your liver enzymes are stable.
Fuzhou, FujianAges 18–70 - NCT06588699RecruitingPhase 2
Digoxin for NASH liver disease study
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
New Haven, ConnecticutAges 18–75 - NCT05842512RecruitingPhase 2
Drug ADI-PEG 20 for NASH in people with mild cirrhosis
This trial tests ADI-PEG 20 against a placebo (inactive pill) to see if it improves liver disease in people with NASH and compensated cirrhosis. It may help by targeting liver fat and inflammation seen on scans and biopsy.
Chiayi City, TaiwanAges 18–80 - NCT04054310Recruiting
Test MRI to measure liver fat and NASH using biopsy
This study checks whether an MRI scan can measure liver health in people with suspected fatty liver disease that may have progressed to NASH. Everyone in the study is also scheduled for a standard liver biopsy, which is used to compare the scan results.
Chandler, ArizonaAges 18–75 - NCT03472157Recruiting
Bariatric surgery for severe NASH with advanced liver scarring
This study tests whether bariatric surgery (either sleeve gastrectomy or Roux-en-Y gastric bypass) improves severe nonalcoholic steatohepatitis (NASH) with advanced liver scarring in people who are obese. You may also need liver biopsies to confirm your liver disease before and after treatment.
LilleAges 18–65 - NCT04371042Recruiting
Study of liver disease and genes in people with fatty liver
This study collects information about metabolic and unexplained (cryptogenic) liver disease and looks at “omics” tests, which are lab tests that measure patterns in blood or tissue to learn what drives the disease. It may help researchers better understand fatty liver and related serious complications, like liver scarring and liver cancer.
Roma, Rome/lazio/italyAges 18 years+ - NCT04366999Recruiting
Bariatric surgery for fatty liver disease in people with obesity
This trial looks at whether weight-loss (bariatric) surgery helps people with fatty liver disease, including “NASH,” and related liver scarring. If you have obesity and a confirmed liver fat diagnosis (and for NASH, biopsy-proven NASH with some fibrosis), the study may follow your outcomes after surgery.
Beijing, Beijing MunicipalityAges 16–65 - NCT06569524RecruitingPhase 2
A new drug for NASH with liver scarring
This study tests a new injected drug (TQA2225/AP025) that may help reduce liver fat and inflammation in people with NASH (a type of fatty liver disease with scarring). It’s for adults who have had a recent liver biopsy and MRI confirming NASH and moderate liver fat.
Lu'an, AnhuiAges 18–75 - NCT06707129Recruiting
New criteria to see if NASH liver scarring has reversed
This study is creating better ways to measure if liver scarring from NASH (a type of fatty liver disease) has improved. It may help doctors know if treatments are working.
Beijing, Beijing MunicipalityAges 18–70 - NCT07581951RecruitingPhase 3
Study of HSK31679 for people with MASH (liver scarring)
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07241195Recruiting
Fatty Liver Study in Older Adults
This study follows older adults with fatty liver disease to understand how their metabolism changes over time and how it affects their overall health. It helps researchers learn more about the condition and its impact on the body outside the liver.
Hangzhou, ZhejiangAges 65–100 - NCT04501406RecruitingPhase 2
Low-dose pioglitazone for fatty liver disease in people with type 2 diabetes
This Phase 2 study tests whether low-dose pioglitazone can improve NASH, a type of fatty liver disease, in adults who also have type 2 diabetes. You may be able to join if your diabetes medicines and lab tests meet specific safety and stability requirements.
Gainesville, FloridaAges 21–75 - NCT06216041RecruitingPhase 1
Safety study of IMM-H014 in healthy adults
This trial tests a new drug called IMM-H014 in healthy volunteers to see if it is safe and how the body processes it. It also checks if food changes how the drug works. You may join if you are generally healthy and meet the age and weight requirements.
Changchun, JilinAges 18–45 - NCT07128797RecruitingPhase 1
Safety and tolerability of B1344 injections for NAFLD
This trial tests whether multiple injections of B1344 are safe and tolerable in people with nonalcoholic fatty liver disease (NAFLD). It aims to find the right dose and check how the drug works in the body.
Beijing, Beijing MunicipalityAges 18–75 - NCT07122700Recruiting
Better tests for fatty liver disease in people with metabolic issues
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
Miami, FloridaAges 18–75 - NCT06879236Recruiting
Digital prevention for fatty liver disease
This trial tests a digital app to help people with fatty liver disease (MASLD) manage their condition. It's for adults who are comfortable using a smartphone or have someone to help them.
Rome, LazioAges 18 years+ - NCT06856252Recruiting
Studying human liver organoids for a fatty liver disease called NASH
This study takes small samples of liver tissue to grow 3D 'mini livers' (organoids) in the lab. Researchers want to learn how non-alcoholic steatohepatitis (NASH), a serious fatty liver condition, starts and progresses, which could lead to better treatments.
Milan, MilanoAges 18 years+ - NCT06843148Recruiting
Does niacin help move fat from liver to fat tissue?
This study tests if niacin (a B vitamin) can help the body store fat safely in fat tissue instead of letting it build up in the liver. It may be an option for people with fatty liver linked to belly fat, without serious liver damage or other health issues.
Sherbrooke, QuebecAges 20–80 - NCT06661655Recruiting
Testing a new ultrasound for liver fat in MASLD patients
This study tests a new ultrasound device that uses sound waves to measure fat in the liver without needles or surgery. It is for people with a type of fatty liver disease called MASLD or MASH, who are already getting an MRI to check their liver.
AngersAges 18–80 - NCT06626074Recruiting
MRI study for NASH diagnosis
This study looks at MRI scans to find better ways to diagnose NASH (a type of fatty liver disease with inflammation). If you are already scheduled for a liver biopsy for suspected NASH, an MRI might help researchers learn more about your condition.
Angers, FranceAges 18 years+
Hear when a new NASH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
NASH trials by city
Studies with a site in or near these metro areas.
NASH trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for nash?
- Yes. Clin2 currently lists 37 recruiting nash studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nash trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nash trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.